Vestcor Inc Takes $204,000 Position in LivaNova PLC (NASDAQ:LIVN)

Vestcor Inc purchased a new stake in LivaNova PLC (NASDAQ:LIVN) during the fourth quarter, HoldingsChannel.com reports. The firm purchased 4,406 shares of the company’s stock, valued at approximately $204,000.

Other large investors also recently made changes to their positions in the company. Nordea Investment Management AB raised its stake in LivaNova by 22.2% during the 4th quarter. Nordea Investment Management AB now owns 68,711 shares of the company’s stock worth $3,188,000 after buying an additional 12,470 shares during the period. Harbor Capital Advisors Inc. acquired a new stake in LivaNova during the 4th quarter worth $1,954,000. KBC Group NV raised its stake in LivaNova by 130.5% during the 4th quarter. KBC Group NV now owns 99,928 shares of the company’s stock worth $4,628,000 after buying an additional 56,580 shares during the period. Rhumbline Advisers raised its stake in LivaNova by 0.5% during the 4th quarter. Rhumbline Advisers now owns 177,938 shares of the company’s stock worth $8,240,000 after buying an additional 899 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in LivaNova by 17.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 621,959 shares of the company’s stock worth $32,678,000 after buying an additional 93,311 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

LIVN has been the topic of several research analyst reports. Mizuho dropped their price objective on LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 26th. Barclays dropped their price target on LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a research note on Friday, March 7th. StockNews.com downgraded LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 26th. Wolfe Research downgraded LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday, February 26th. Finally, The Goldman Sachs Group dropped their price target on LivaNova from $64.00 to $55.00 and set a “buy” rating on the stock in a research note on Monday, March 3rd. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, LivaNova has an average rating of “Moderate Buy” and a consensus price target of $61.17.

LivaNova Price Performance

Shares of NASDAQ LIVN opened at $40.41 on Wednesday. The stock has a market capitalization of $2.20 billion, a price-to-earnings ratio of 96.21 and a beta of 1.10. The business has a 50-day moving average of $45.75 and a 200-day moving average of $48.94. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. LivaNova PLC has a fifty-two week low of $36.85 and a fifty-two week high of $64.48.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.